Table 1

Median Sharp van der Heijde scores (M) and interquartile ranges (IQR; 25%–75% centiles) per genotype for patients with ACPA+ RA (n = number of patients). Genotypes were combined for rs1878658 (G), rs10499194 (T) and rs6920220 (A), as the frequency of patients homozygous for the respective minor allele was ≤5% for these single nucleotide polymorphisms

	Year
	0			1			2			3			4			5
ACPA+	M	IQR	n	M	IQR	n	M	IQR	n	M	IQR	n	M	IQR	n	M	IQR	n
rs1878658
AA	6	2–13	126	14	6–24	111	18	10–32	113	22.5	11–42	98	26.5	14–51.5	86	32	14–51.5	89
AG/GG	3	1–7	40	12	5.5–20.5	40	17	6–32	39	30	11.5–56.5	34	32	16–69	31	27	17–74	31
rs675520
AA	9	4.5–13	33	14	6.5–21	32	15	8–27.5	33	19	9–34	27	22	13.5–39.5	24	20	12.5–47.5	21
AG	5	1–10	83	12	5–21	73	18	9.5–32.5	78	25	11.5–54	68	32.5	14–61	58	33	17–62.5	66
GG	5	2–11	51	14	7–27	48	18	8–37	43	26	14–48	39	28	16–63	37	32	20–64	35
AG/GG	5	2–10	134	13	6–24.5	121	18	9.5–33	121	26	12–53	107	32	15–61	95	32	18.5–61	101
rs9376293
CC	6.5	3–13.5	28	15	9–28	27	27	12–49.5	25	33	15.5–58	24	35	16.5–62	24	35	16.5–56	21
CT	4	1–9	84	12	5–21	79	17	7–32.5	78	21	10.5–54	66	32	14–68	57	36	20–68	61
TT	8	3–13	54	14	6–21	46	16	10.5–25.5	50	21	12–30.5	44	23	13.5–38	38	23	13–47	40
CC/CT	4	2–10	112	13	6–26.5	106	18	8–36	103	28	11–54.5	90	34	15–63	81	36	19–67.5	82
rs10499194
CC	7	2–12.5	90	14	6–21.5	77	18	9.5–28	82	21	12–35	71	25.5	14–45	62	29	14–48	62
CT/TT	4	2–7.5	65	12	6–24.5	64	17	7–37	61	31	11–55	55	29.5	14.5–67	50	32	15–68	51
rs6920220
AA/AG	7	2–12	58	14	6–21	53	20	10–32.5	57	24	12–48	47	32	18–56	35	35.5	18–65	42
GG	4.5	2–10.5	108	13	6–25	99	16.5	8–30.5	96	22	11–48	86	25	14–61	84	24	14–51	79

ACPA, anti-citrullinated protein/peptide antibodies; RA, rheumatoid arthritis.